Genetically Engineered Mouse Models in Cancer Research

Advances in Cancer Research

Volumn 106, Issue , 2010, Pages 113-164

  Walrath, Jessica C ^a   Hawes, Jessica J ^a   Van Dyke, Terry ^a   Reilly, Karlyne M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; DISEASE MODEL; EXPERIMENTAL NEOPLASM; GENETIC ENGINEERING; HUMAN; MEDICAL RESEARCH; MOUSE; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL;

EID: 77954637445     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/S0065-230X(10)06004-5     Document Type: Chapter

References (261)

1. Adams, J.M., Strasser, A., Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res. 68 (2008), 4018–4021.
2. Adams, D.J., et al. Mutagenic insertion and chromosome engineering resource (MICER). Nat. Genet. 36 (2004), 867–871.
3. Akagi, K., et al. RTCGD: Retroviral tagged cancer gene database. Nucleic Acids Res. 32 (2004), D523–D527.
4. Allinen, M., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 (2004), 17–32.
5. Arbeit, J.M., et al. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68 (1994), 4358–4368.
6. Artandi, S.E., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000), 641–645.
7. Attardi, L.D., Donehower, L.A., Probing p53 biological functions through the use of genetically engineered mouse models. Mutat. Res. 576 (2005), 4–21.
8. Balkwill, F., Coussens, L.M., Cancer: An inflammatory link. Nature 431 (2004), 405–406.
9. Bardeesy, N., et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 103 (2006), 5947–5952.
10. Barlow, C., et al. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86 (1996), 159–171.
11. Baron, U., et al. Tetracycline-controlled transcription in eukaryotes: Novel transactivators with graded transactivation potential. Nucleic Acids Res. 25 (1997), 2723–2729.
12. Becher, O.J., Holland, E.C., Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 66 (2006), 3355–3358 discussion 3358–3359.
13. Ben David, Y., et al. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene 3 (1988), 179–185.
14. Berger, S.L., et al. Selective inhibition of activated but not basal transcription by the acidic activation domain of VP16: Evidence for transcriptional adaptors. Cell 61 (1990), 1199–1208.
15. Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003), 401–410.
16. Bergers, G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000), 737–744.
17. Bibby, M.C., Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur. J. Cancer 40 (2004), 852–857.
18. Bibikova, M., et al. Human embryonic stem cells have a unique epigenetic signature. Genome Res. 16 (2006), 1075–1083.
19. Bockamp, E., et al. Conditional transgenic mouse models: From the basics to genome-wide sets of knockouts and current studies of tissue regeneration. Regen. Med. 3 (2008), 217–235.
20. Branda, C.S., Dymecki, S.M., Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev. Cell 6 (2004), 7–28.
21. Broman, K.W., The genomes of recombinant inbred lines. Genetics 169 (2005), 1133–1146.
22. Brown, S.D., et al. Quiet as a mouse: Dissecting the molecular and genetic basis of hearing. Nat. Rev. Genet. 9 (2008), 277–290.
23. Buchholz, F., et al. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep. 1 (2000), 133–139.
24. Capecchi, M.R., Gene targeting in mice: Functional analysis of the mammalian genome for the twenty-first century. Nat. Rev. Genet. 6 (2005), 507–512.
25. Carver, B.S., Pandolfi, P.P., Mouse modeling in oncologic preclinical and translational research. Clin. Cancer Res. 12 (2006), 5305–5311.
26. Chai, Y., et al. Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development 127 (2000), 1671–1679.
27. Chambers, A.F., et al. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2 (2000), 400–407.
28. Chang, S., et al. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J. Clin. Invest. 119 (2009), 3160–3171.
29. Chesler, E.J., et al. The Collaborative Cross at Oak Ridge National Laboratory: Developing a powerful resource for systems genetics. Mamm. Genome 19 (2008), 382–389.
30. Chin, L., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97 (1999), 527–538.
31. Cho, B.C., et al. Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J. Virol. 69 (1995), 7138–7146.
32. Churchill, G.A., et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36 (2004), 1133–1137.
33. Cichowski, K., et al. Mouse models of tumor development in neurofibromatosis type 1. Science 286 (1999), 2172–2176.
34. Collier, L.S., et al. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436 (2005), 272–276.
35. Collier, L.S., et al. Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res. 69 (2009), 8429–8437.
36. Collins, E.C., et al. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep. 1 (2000), 127–132.
37. Cormier, R.T., et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 17 (1997), 88–91.
38. Coussens, L.M., et al. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149 (1996), 1899–1917.
39. Coussens, L.M., et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13 (1999), 1382–1397.
40. Crabtree, J.S., et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl. Acad. Sci. USA 98 (2001), 1118–1123.
41. Crawford, N.P., et al. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res., 8, 2006, R16.
42. Crawford, Y., Ferrara, N., VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res. 335 (2009), 261–269.
43. Cronin, C.A., et al. The lac operator–repressor system is functional in the mouse. Genes Dev. 15 (2001), 1506–1517.
44. Cullen, B.R., Transcription and processing of human microRNA precursors. Mol. Cell. 16 (2004), 861–865.
45. D'Angelo, M., et al. Angiogenesis in transgenic models of multistep carcinogenesis. J. Neurooncol. 50 (2000), 89–98.
46. Demant, P., Cancer susceptibility in the mouse: Genetics, biology and implications for human cancer. Nat. Rev. Genet. 4 (2003), 721–734.
47. De Palma, M., et al. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum. Gene Ther. 14 (2003), 1193–1206.
48. de Visser, K.E., Coussens, L.M., The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 13 (2006), 118–137.
49. de Visser, K.E., et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 (2005), 411–423.
50. de Visser, K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006), 24–37.
51. Dickins, R.A., et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat. Genet. 39 (2007), 914–921.
52. Dietrich, W.F., et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75 (1993), 631–639.
53. Ding, S., et al. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122 (2005), 473–483.
54. Dragani, T.A., 10 years of mouse cancer modifier loci: Human relevance. Cancer Res. 63 (2003), 3011–3018.
55. Dragatsis, I., Zeitlin, S., A method for the generation of conditional gene repair mutations in mice. Nucleic Acids Res., 29, 2001, E10.
56. DuPage, M., et al. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4 (2009), 1064–1072.
57. Dupuy, A.J., et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436 (2005), 221–226.
58. Dupuy, A.J., et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 69 (2009), 8150–8156.
59. Eden, A., et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 300, 2003, 455.
60. Engle, S.J., et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res. 62 (2002), 6362–6366.
61. Evers, B., Jonkers, J., Mouse models of BRCA1 and BRCA2 deficiency: Past lessons, current understanding and future prospects. Oncogene 25 (2006), 5885–5897.
62. Fearon, E., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61 (1990), 759–767.
63. Fidler, I.J., Kripke, M.L., Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (1977), 893–895.
64. Flint, J., et al. Strategies for mapping and cloning quantitative trait genes in rodents. Nat. Rev. Genet. 6 (2005), 271–286.
65. Folkman, J., Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 175 (1972), 409–416.
66. Forster, A., et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3 (2003), 449–458.
67. Forster, A., et al. Chromosomal translocation engineering to recapitulate primary events of human cancer. Cold Spring Harb. Symp. Quant. Biol. 70 (2005), 275–282.
68. Forster, A., et al. The invertor knock-in conditional chromosomal translocation mimic. Nat. Methods 2 (2005), 27–30.
69. Frese, K.K., Tuveson, D.A., Maximizing mouse cancer models. Nat. Rev. Cancer 7 (2007), 645–658.
70. Friedel, R.H., et al. EUCOMM—The European conditional mouse mutagenesis program. Brief Funct. Genomic Proteomic 6 (2007), 180–185.
71. Friedrich, G., Soriano, P., Promoter traps in embryonic stem cells: A genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5 (1991), 1513–1523.
72. Fujii, S., Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol. 29 (2008), 242–249.
73. Gaudet, F., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003), 489–492.
74. Gerber, H.P., et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. USA 104 (2007), 3478–3483.
75. German, J., Bloom syndrome: A mendelian prototype of somatic mutational disease. Medicine (Baltimore) 72 (1993), 393–406.
76. Giraudo, E., et al. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114 (2004), 623–633.
77. Gonzalez-Murillo, A., et al. Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors. Blood 112 (2008), 3138–3147.
78. Goodlad, R.A., et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 27 (2006), 2133–2139.
79. Goss, K.H., et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297 (2002), 2051–2053.
80. Gossen, M., Bujard, H., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89 (1992), 5547–5551.
81. Gossen, J.A., et al. Efficient rescue of integrated shuttle vectors from transgenic mice: A model for studying mutations in vivo. Proc. Natl. Acad. Sci. USA 86 (1989), 7971–7975.
82. Gould, K.A., et al. Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice. Genetics 144 (1996), 1769–1776.
83. Greten, F.R., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004), 285–296.
84. Grinspan, J.B., et al. Re-entry into the cell cycle is required for bFGF-induced oligodendroglial dedifferentiation and survival. J. Neurosci. Res. 46 (1996), 456–464.
85. Gross, L., Viral etiology of cancer and leukemia: A look into the past, present and future—G.H.A. Clowes Memorial Lecture. Cancer Res. 38 (1978), 485–493.
86. Gupta, P.B., et al. Cancer stem cells: Mirage or reality?. Nat. Med. 15 (2009), 1010–1012.
87. Gutmann, D.H., et al. Harnessing preclinical mouse models to inform human clinical cancer trials. J. Clin. Invest. 116 (2006), 847–852.
88. Haas-Kogan, D.A., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97 (2005), 880–887.
89. Hager, J.H., Hanahan, D., Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann. NY Acad. Sci. 887 (1999), 150–163.
90. Hambardzumyan, D., et al. Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev. 4 (2008), 203–210.
91. Hande, M.P., DNA repair factors and telomere-chromosome integrity in mammalian cells. Cytogenet. Genome Res. 104 (2004), 116–122.
92. Hansen, G.M., et al. Large-scale gene trapping in C57BL/6N mouse embryonic stem cells. Genome Res. 18 (2008), 1670–1679.
93. Hill, R., et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 (2005), 1001–1011.
94. Hirai, H., et al. Oncogenic mechanisms of Evi-1 protein. Cancer Chemother. Pharmacol. 48:Suppl 1 (2001), S35–S40.
95. Hirasawa, R., et al. Maternal and zygotic Dnmt1 are necessary and sufficient for the maintenance of DNA methylation imprints during preimplantation development. Genes Dev. 22 (2008), 1607–1616.
96. Hoffman, R.M., Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin. Exp. Metastasis 26 (2009), 345–355.
97. Hosoda, T., et al. Clonality of mouse and human cardiomyogenesis in vivo. Proc. Natl. Acad. Sci. USA 106 (2009), 17169–17174.
98. Hunter, K.W., Crawford, N.P., The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. Annu. Rev. Genet. 42 (2008), 131–141.
99. Hunter, K.W., et al. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res. 61 (2001), 8866–8872.
100. Huse, J.T., Holland, E.C., Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 19 (2009), 132–143.
101. Husemann, Y., Klein, C.A., The analysis of metastasis in transgenic mouse models. Transgenic Res. 18 (2009), 1–5.
102. Husemann, Y., et al. Systemic spread is an early step in breast cancer. Cancer Cell 13 (2008), 58–68.
103. Iraqi, F.A., et al. The Collaborative Cross, developing a resource for mammalian systems genetics: A status report of the Wellcome Trust cohort. Mamm. Genome 19 (2008), 379–381.
104. Ivics, Z., et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91 (1997), 501–510.
105. Jackson, E.L., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15 (2001), 3243–3248.
106. Jackson, M., et al. Severe global DNA hypomethylation blocks differentiation and induces histone hyperacetylation in embryonic stem cells. Mol. Cell. Biol. 24 (2004), 8862–8871.
107. Jemal, A., et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl. Cancer Inst. 100 (2008), 1672–1694.
108. Jiang, X., et al. Fate of the mammalian cardiac neural crest. Development 127 (2000), 1607–1616.
109. Johnson, L., et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410 (2001), 1111–1116.
110. Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128 (2007), 683–692.
111. Jonkers, J., Berns, A., Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys. Acta 1287 (1996), 29–57.
112. Kado, S., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res. 61 (2001), 2395–2398.
113. Kamijo, T., et al. Tumor spectrum in ARF-deficient mice. Cancer Res. 59 (1999), 2217–2222.
114. Kanai, Y., Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol. Int. 58 (2008), 544–558.
115. Kang, J.H., Chung, J.K., Molecular-genetic imaging based on reporter gene expression. J. Nucl. Med. 49:Suppl 2 (2008), 164S–179S.
116. Karlseder, J., et al. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283 (1999), 1321–1325.
117. Keng, V.W., et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 27 (2009), 264–274.
118. Khanna, C., Hunter, K., Modeling metastasis in vivo. Carcinogenesis 26 (2005), 513–523.
119. Khanna, C., et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10 (2004), 182–186.
120. Kim, C.F., et al. Mouse models of human non-small-cell lung cancer: Raising the bar. Cold Spring Harb. Symp. Quant. Biol. 70 (2005), 241–250.
121. Kim, M., et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125 (2006), 1269–1281.
122. Kohler, S.W., et al. Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ. Mol. Mutagen. 18 (1991), 316–321.
123. Kool, J., Berns, A., High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat. Rev. Cancer 9 (2009), 389–399.
124. Korsisaari, N., et al. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc. Natl. Acad. Sci. USA 104 (2007), 10625–10630.
125. Korsisaari, N., et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin. Cancer Res. 14 (2008), 249–258.
126. Kost-Alimova, M., Imreh, S., Modeling non-random deletions in cancer. Semin. Cancer Biol. 17 (2007), 19–30.
127. Kundu, J.K., Surh, Y.J., Inflammation: Gearing the journey to cancer. Mutat. Res. 659 (2008), 15–30.
128. Lakso, M., et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc. Natl. Acad. Sci. USA 89 (1992), 6232–6236.
129. Lambert, R., Diversity Outbred and Collaborative Cross mice to offer maximum allelic variation. Jax Notes, Vol. 514., 2009, The Jackson Laboratory, Bar Harbor, ME, 2.
130. Lang, G.A., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004), 861–872.
131. Largaespada, D.A., et al. Retroviral insertion at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady state ras-GTP levels. J. Virol. 69 (1995), 5095–5102.
132. Lawlor, E.R., et al. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res. 66 (2006), 4591–4601.
133. Lee, H.W., et al. Essential role of mouse telomerase in highly proliferative organs. Nature 392 (1998), 569–574.
134. Lee, E.M., et al. Xenograft models for the preclinical evaluation of new therapies in acute leukemia. Leuk. Lymphoma 48 (2007), 659–668.
135. Lee, J., et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13 (2008), 69–80.
136. Legrand, N., et al. Humanized mice for modeling human infectious disease: Challenges, progress, and outlook. Cell Host Microbe 6 (2009), 5–9.
137. Lei, H., et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122 (1996), 3195–3205.
138. LePage, D.F., Conlon, R.A., Animal models for disease: Knockout, knock-in, and conditional mutant mice. Methods Mol. Med. 129 (2006), 41–67.
139. Lessard, J., Sauvageau, G., Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 (2003), 255–260.
140. Lifsted, T., et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int. J. Cancer 77 (1998), 640–644.
141. Lin, E.Y., et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001), 727–740.
142. Lipsick, J.S., Wang, D.M., Transformation by v-Myb. Oncogene 18 (1999), 3047–3055.
143. Liu, X., et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 104 (2007), 12111–12116.
144. Lobato, M.N., et al. Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias. J. Natl. Cancer Inst. Monogr. 39 (2008), 58–63.
145. Lozano, G., Behringer, R.R., New mouse models of cancer: Single-cell knockouts. Proc. Natl. Acad. Sci. USA 104 (2007), 4245–4246.
146. Luo, G., et al. Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nat. Genet. 26 (2000), 424–429.
147. Lyons, S.K., Advances in imaging mouse tumour models in vivo. J. Pathol. 205 (2005), 194–205.
148. Macleod, K.F., Jacks, T., Insights into cancer from transgenic mouse models. J. Pathol. 187 (1999), 43–60.
149. MacPhee, M., et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81 (1995), 957–966.
150. Maddison, K., Clarke, A.R., New approaches for modelling cancer mechanisms in the mouse. J. Pathol. 205 (2005), 181–193.
151. Maedler, K., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110 (2002), 851–860.
152. Maggi, A., et al. Techniques: Reporter mice—A new way to look at drug action. Trends Pharmacol. Sci. 25 (2004), 337–342.
153. Martinez, R., et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4 (2009), 255–264.
154. Marumoto, T., et al. Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15 (2009), 110–116.
155. Maser, R.S., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447 (2007), 966–971.
156. Meister, G., Tuschl, T., Mechanisms of gene silencing by double-stranded RNA. Nature 431 (2004), 343–349.
157. Mellinghoff, I.K., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353 (2005), 2012–2024.
158. Metzger, D., Chambon, P., Site- and time-specific gene targeting in the mouse. Methods 24 (2001), 71–80.
159. Mikkola, H.K., Orkin, S.H., Gene targeting and transgenic strategies for the analysis of hematopoietic development in the mouse. Methods Mol. Med. 105 (2005), 3–22.
160. Momota, H., Holland, E.C., Bioluminescence technology for imaging cell proliferation. Curr. Opin. Biotechnol. 16 (2005), 681–686.
161. Montini, E., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119 (2009), 964–975.
162. Moon, J.H., et al. Induction of neural stem cell-like cells (NSCLCs) from mouse astrocytes by Bmi1. Biochem. Biophys. Res. Commun. 371 (2008), 267–272.
163. Morahan, G., et al. Establishment of “The Gene Mine”: A resource for rapid identification of complex trait genes. Mamm. Genome 19 (2008), 390–393.
164. Morishita, K., et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54 (1988), 831–840.
165. Moser, A.R., et al. The Min (multiple intestinal neoplasia) mutation: Its effect on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol. 116 (1992), 1517–1526.
166. Mowat, M., et al. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 314 (1985), 633–636.
167. Muzumdar, M.D., et al. Modeling sporadic loss of heterozygosity in mice by using mosaic analysis with double markers (MADM). Proc. Natl. Acad. Sci. USA 104 (2007), 4495–4500.
168. Nadeau, J.H., et al. Analysing complex genetic traits with chromosome substitution strains. Nat. Genet. 24 (2000), 221–225.
169. Ngan, E.S., et al. The mifepristone-inducible gene regulatory system in mouse models of disease and gene therapy. Semin. Cell Dev. Biol. 13 (2002), 143–149.
170. Niwa, H., How is pluripotency determined and maintained?. Development 134 (2007), 635–646.
171. No, D., et al. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93 (1996), 3346–3351.
172. Nohmi, T., et al. Recent advances in the protocols of transgenic mouse mutation assays. Mutat. Res. 455 (2000), 191–215.
173. Normanno, N., et al. Target-based therapies in breast cancer: Current status and future perspectives. Endocr. Relat. Cancer 16 (2009), 675–702.
174. Odelberg, S.J., Inducing cellular dedifferentiation: A potential method for enhancing endogenous regeneration in mammals. Semin. Cell Dev. Biol. 13 (2002), 335–343.
175. O'Hagan, R.C., et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2 (2002), 149–155.
176. Okano, M., et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999), 247–257.
177. Olive, K.P., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
178. Parangi, S., et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93 (1996), 2002–2007.
179. Park, I.K., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (2003), 302–305.
180. Park, Y.G., et al. Multiple cross and inbred strain haplotype mapping of complex-trait candidate genes. Genome Res. 13 (2003), 118–121.
181. Park, Y.G., et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat. Genet. 37 (2005), 1055–1062.
182. Peeper, D., Berns, A., Cross-species oncogenomics in cancer gene identification. Cell 125 (2006), 1230–1233.
183. Pegram, M., Ngo, D., Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): A case study. Adv. Drug Deliv. Rev. 58 (2006), 723–734.
184. Pelengaris, S., et al. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109 (2002), 321–334.
185. Peters, L.L., et al. The mouse as a model for human biology: A resource guide for complex trait analysis. Nat. Rev. Genet. 8 (2007), 58–69.
186. Pikarsky, E., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004), 461–466.
187. Porret, A., et al. Tissue-specific transgenic and knockout mice. Methods Mol. Biol. 337 (2006), 185–205.
188. Pritchard, J.B., et al. The role of transgenic mouse models in carcinogen identification. Environ. Health Perspect. 111 (2003), 444–454.
189. Prosser, H., Bradley, A., Transgenics at breaking-point. Cancer Cell 3 (2003), 411–413.
190. Qiu, T.H., et al. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: Correlation to human disease. Cancer Res. 64 (2004), 5973–5981.
191. Qiu, W., et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 40 (2008), 650–655.
192. Quintana, E., et al. Efficient tumour formation by single human melanoma cells. Nature 456 (2008), 593–598.
193. Ramaswamy, S., et al. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33 (2003), 49–54.
194. Reilly, K.M., et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 26 (2000), 109–113.
195. Reilly, K.M., et al. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res. 66 (2006), 62–68.
196. Richmond, A., Su, Y., Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Model Mech. 1 (2008), 78–82.
197. Riggins, G.J., et al. Absence of secretory phospholipase A2 gene alterations in human colorectal cancer. Cancer Res. 55 (1995), 5184–5186.
198. Sandy, P., et al. Mammalian RNAi: A practical guide. Biotechniques. 39 (2005), 215–224.
199. Sausville, E.A., Burger, A.M., Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66 (2006), 3351–3354 discussion 3354.
200. Schnutgen, F., et al. Genomewide production of multipurpose alleles for the functional analysis of the mouse genome. Proc. Natl. Acad. Sci. USA 102 (2005), 7221–7226.
201. Sharan, S.K., et al. Recombineering: A homologous recombination-based method of genetic engineering. Nat. Protoc. 4 (2009), 206–223.
202. Sharpless, N.E., Depinho, R.A., The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5 (2006), 741–754.
203. Shchors, K., Evan, G., Tumor angiogenesis: Cause or consequence of cancer?. Cancer Res. 67 (2007), 7059–7061.
204. Shchors, K., et al. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 20 (2006), 2527–2538.
205. Shizuya, H., et al. Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc. Natl. Acad. Sci. USA 89 (1992), 8794–8797.
206. Shore, S.K., et al. Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene 21 (2002), 8568–8576.
207. Silva, J.M., et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37 (2005), 1281–1288.
208. Singer, O., Verma, I.M., Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr. Gene Ther. 8 (2008), 483–488.
209. Skarnes, W.C., et al. A public gene trap resource for mouse functional genomics. Nat. Genet. 36 (2004), 543–544.
210. Soriano, P., Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21 (1999), 70–71.
211. Soverini, S., et al. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev. Anticancer Ther. 8 (2008), 853–864.
212. Starr, T.K., et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323 (2009), 1747–1750.
213. Stegmeier, F., et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA 102 (2005), 13212–13217.
214. Steindler, D.A., Laywell, E.D., Astrocytes as stem cells: Nomenclature, phenotype, and translation. Glia 43 (2003), 62–69.
215. Stern, P., et al. A system for Cre-regulated RNA interference in vivo. Proc. Natl. Acad. Sci. USA 105 (2008), 13895–13900.
216. Suzuki, T., et al. Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. EMBO J. 25 (2006), 3422–3431.
217. Swing, D.A., Sharan, S.K., BAC rescue: A tool for functional analysis of the mouse genome. Methods Mol. Biol. 256 (2004), 183–198.
218. Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
219. Tan, B.T., et al. The cancer stem cell hypothesis: A work in progress. Lab. Invest. 86 (2006), 1203–1207.
220. Tan, S.H., et al. Pharmacogenetics in breast cancer therapy. Clin. Cancer Res. 14 (2008), 8027–8041.
221. Teicher, B.A., In vivo/ex vivo and in situ assays used in cancer research: A brief review. Toxicol. Pathol. 37 (2009), 114–122.
222. Terabe, M., Berzofsky, J.A., NKT cells in immunoregulation of tumor immunity: A new immunoregulatory axis. Trends Immunol. 28 (2007), 491–496.
223. Terabe, M., Berzofsky, J.A., The role of NKT cells in tumor immunity. Adv. Cancer Res. 101 (2008), 277–348.
224. Theurillat, J.P., et al. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am. J. Pathol. 154 (1999), 581–590.
225. Tiscornia, G., et al. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc. Natl. Acad. Sci. USA 101 (2004), 7347–7351.
226. Tlsty, T.D., Coussens, L.M., Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1 (2006), 119–150.
227. To, C., et al. The Centre for Modeling Human Disease Gene Trap resource. Nucleic Acids Res. 32 (2004), D557–D559.
228. Tomlinson, I.P., et al. Variants at the secretory phospholipase A2 (PLA2G2A) locus: Analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours. Ann. Hum. Genet. 60 (1996), 369–376.
229. Troiani, T., et al. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit. Rev. Oncol. Hematol. 65 (2008), 200–211.
230. Uren, A.G., et al. Retroviral insertional mutagenesis: Past, present and future. Oncogene 24 (2005), 7656–7672.
231. Uren, A.G., et al. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 133 (2008), 727–741.
232. Valdar, W., et al. Simulating the collaborative cross: Power of quantitative trait loci detection and mapping resolution in large sets of recombinant inbred strains of mice. Genetics 172 (2006), 1783–1797.
233. van der Weyden, L., et al. Chromosome engineering in ES cells. Methods Mol. Biol. 530 (2009), 49–77.
234. Van Dyke, T., Jacks, T., Cancer modeling in the modern era: Progress and challenges. Cell 108 (2002), 135–144.
235. van Lohuizen, M., Berns, A., Tumorigenesis by slow-transforming retroviruses—An update. Biochim. Biophys. Acta 1032 (1990), 213–235.
236. van Lohuizen, M., et al. N-myc is frequently activated by proviral insertion in MuLV-induced T cell lymphomas. EMBO J. 8 (1989), 133–136.
237. van Lohuizen, M., et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65 (1991), 737–752.
238. van 't Veer, L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002), 530–536.
239. Ventura, A., et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. USA 101 (2004), 10380–10385.
240. Walrath, J.C., et al. Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mamm. Genome 20 (2009), 214–223.
241. Wang, X., Paigen, B., Genetics of variation in HDL cholesterol in humans and mice. Circ. Res. 96 (2005), 27–42.
242. Wang, X.J., et al. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc. Natl. Acad. Sci. USA 96 (1999), 8483–8488.
243. Wang, X., et al. Identifying novel genes for atherosclerosis through mouse-human comparative genetics. Am. J. Hum. Genet. 77 (2005), 1–15.
244. Wang, W., et al. Induced mitotic recombination of p53 in vivo. Proc. Natl. Acad. Sci. USA 104 (2007), 4501–4505.
245. Wei, K., et al. Mouse models for human DNA mismatch-repair gene defects. Trends Mol. Med. 8 (2002), 346–353.
246. Weinberg, R.A., Is metastasis predetermined?. Mol. Oncol. 1 (2007), 263–264 author reply 265–266.
247. Weinberg, R.A., Coevolution in the tumor microenvironment. Nat. Genet. 40 (2008), 494–495.
248. Westbrook, T.F., et al. Dissecting cancer pathways and vulnerabilities with RNAi. Cold Spring Harb. Symp. Quant. Biol. 70 (2005), 435–444.
249. Westphal, C.H., et al. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Genet. 16 (1997), 397–401.
250. Wilson, M.H., et al. PiggyBac transposon-mediated gene transfer in human cells. Mol. Ther. 15 (2007), 139–145.
251. Yamamoto, M., et al. A multifunctional reporter mouse line for Cre- and FLP-dependent lineage analysis. Genesis 47 (2009), 107–114.
252. Yang, H., et al. Metastasis predictive signature profiles pre-exist in normal tissues. Clin. Exp. Metastasis 22 (2005), 593–603.
253. Yang, F.C., et al. Nf1-dependent tumors require a microenvironment containing Nf1+/– and c-kit-dependent bone marrow. Cell 135 (2008), 437–448.
254. Yu, L., et al. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest. Ophthalmol. Vis. Sci. 49 (2008), 522–527.
255. Zardo, G., et al. Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: Therapeutic potential of cell reprogramming. Leukemia 22 (2008), 1503–1518.
256. Zender, L., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006), 1253–1267.
257. Zeng, Y., et al. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9 (2002), 1327–1333.
258. Zheng, L., Lee, W.H., Retinoblastoma tumor suppressor and genome stability. Adv. Cancer Res. 85 (2002), 13–50.
259. Zheng, H., et al. Induction of abnormal proliferation by nonmyelinating Schwann cells triggers neurofibroma formation. Cancer Cell 13 (2008), 117–128.
260. Zhu, Y., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296 (2002), 920–922.
261. Zhu, Y., et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8 (2005), 119–130.